Expression of MRP1 gene in acute leukemia
Keywords:
Multidrug resistance, Chemotherapy, Polymerase chain reaction, Leukemia, myeloid, Leukemia, lymphoblastic, acuteAbstract
CONTEXT AND OBJECTIVE: Overexpression of the multidrug resistance-associated protein 1 (MRP1) gene has been linked with resistance to chemotherapy in vitro, but little is known about its clinical impact on acute leukemia patients. Our aim was to investigate the possible association between MRP1 gene expression level and clinical outcomes among Iranian leukemia patients. DESIGN AND SETTING: This was an analytical cross-sectional study on patients referred to the Hematology, Oncology and Stem Cell Research Center, Sharyatee Public Hospital, whose diagnosis was acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL). All molecular work was performed at NIGEB (public institution). METHODS: To correlate with prognostic markers and the clinical outcome of acute leukemia, MRP1 gene expression was assessed in 35 AML cases and 17 ALL cases, using the quantitative real-time polymerase chain reaction and comparing this to the chemotherapy response type. RESULTS: Mean expression in AML patients in complete remission (0.032 ± 0.031) was significantly lower than in relapsed cases (0.422 ± 0.297). In contrast, no signifi cant difference in MRP1 mRNA level was observed between complete remission and relapsed ALL patients. There was a difference in MRP1 expression between patients with unfavorable and favorable cytogenetic prognosis (0.670 ± 0.074 and 0.028 ± 0.013, respectively). MRP1 expression in M5 was signifi cantly higher (p-value = 0.001) than in other subtypes. CONCLUSIONS: The fi ndings suggest that high MRP1 expression was associated with poor clinical outcome and was correlated with the M5 subtype and poor cytogenetic subgroups among AML patients but not among ALL patients.
Downloads
References
Sonneveld P. Multidrug resistance in haematological malignan- cies. J Intern Med. 2000;247(5):521-34.
Büchner T. Treatment of adult acute leukemia. Curr Opin Oncol. 1997;9(1):18-25.
Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer. 1996;32A(6):1034-8.
Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258(5088):1650-4.
Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54(2):357-61.
Legrand O, Perrot JY, Simonin G, Baudard M, Marie JP. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood. 2001;97(2):502-8.
Solary E, Drenou B, Campos L, et al. Quinine as a multi- drug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood. 2003;102(4):1202-10.
Broxterman HJ, Sonneveld P, Pieters R, et al. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia. 1999;13(2):258-65.
Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85(7):711-21.
Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol. 1998;53(1):141-7.
Legrand O, Zittoun R, Marie JP. Role of MRP1 in mul- tidrug resistance in acute myeloid leukemia. Leukemia. 1999;13(4):578-84.
Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 1998;20(11):931-40.
Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP- binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2(7):685-98.
Beck WT, Grogan TM. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia. 1997;11(7):1107-9.
Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res. 1996;56(13):3010-20.
Ohno N, Tani A, Chen ZS, et al. Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res. 2001;7(10):3120-6.
Plasschaert SL, Vellenga E, de Bont ES, et al. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma. 2003;44(1):85-95.
Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol. 1999;104(2):328-35.
Mitelman F. ISCN 1995. An international system for human cytogenetic nomenclature. Basel: Karger; 1995.
Mitelman F. ISCN 1991. Guidelines for cancer cytogenetics: supplement to an international system for human cytogenetic nomenclature. Basel: Karger; 1991.
Bailly JD, Muller C, Jaffrézou JP, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cells lines. Leukemia. 1995;9(5):799-807.
Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resis- tance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995;9(10):1661-6.
Fujimaki S, Funato T, Harigae H, et al. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem. 2002;48(6 Pt 1):811-7.
Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res. 1997;3(8):1419-25.
den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998:91(6):2092-8.
van der Kolk DM, de Vries EG, Noordhoek L, et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia. 2001;15(10):1544-53.
Steinbach D, Friedrich J, Dawczynski K, et al. Are MTT assays the right tool to analyze drug resistance caused by ABC-transporters in patient samples? Leuk Lymphoma. 2005;46(9):1357-63.
Yague E, Armesilla AL, Harrison G, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem. 2003;278(12):10344-52.
Manohar CF, Bray JA, Salwen HR, et al. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene. 2004;23(3):753-62.
Zhu G, Chang Y, Zuo J, et al. Fudenine, a C-terminal truncated rat homologue of mouse prominin, is blood glucose-regulated and can up-regulate the expression of GAPDH. Biochem Bio- phys Res Commun. 2001;281(4):951-6.
Goidin D, Mamessier A, Staquet MJ, Schmitt D, Berthier- Vergnes O. Ribosomal 18S RNA prevails over glyceraldehyde- 3-phosphate dehydrogenase and beta-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal Biochem. 2001;295(1):17-21.
Oselin K, Mrozikiewicz PM, Pähkla R, Roots I. Quantitative determination of the human MRP1 and MRP2 mRNA expres- sion in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol. 2003;71(2):119-23.
Kuss BJ, Deeley RG, Cole SP, et al. Deletion of gene for multidrug resistance in acute myeloid leukemia with inver- sion in chromosome 16: prognostic implications. Lancet. 1994;343(8912):1531-4.
Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clini- cal significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94(3):1086-99.
